# Hydroxychloroquine in Outpatient Adults With COVID-19

> **NCT04333654** · PHASE1 · TERMINATED · sponsor: **Sanofi** · enrollment: 8 (actual)

## Conditions studied

- Coronavirus Infection

## Interventions

- **DRUG:** Hydroxychloroquine SAR321068
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04333654
- **Lead sponsor:** Sanofi
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2020-04-12
- **Primary completion:** 2020-05-26
- **Final completion:** 2020-05-26
- **Target enrollment:** 8 (ACTUAL)
- **Why stopped:** Rate of enrollment too slow to allow completion in a reasonable timeframe
- **Last updated:** 2025-09-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04333654

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04333654, "Hydroxychloroquine in Outpatient Adults With COVID-19". Retrieved via AI Analytics 2026-07-12 from https://api.ai-analytics.org/clinical/NCT04333654. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*